Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

Andrew L. Schmidt; Ziad Bakouny; Sheena Bhalla; John A. Steinharter; Douglas A. Tremblay; Mark M. Awad; Alaina J. Kessler; Robert I. Haddad; Michelle Evans; Fiona Busser; Michael Wotman; Catherine R. Curran; Brittney S. Zimmerman; Gabrielle Bouchard; Tomi Jun; Pier V. Nuzzo; Qian Qin; Laure Hirsch; Jonathan Feld; Kaitlin M. Kelleher; Danielle Seidman; Hsin Hui Huang; Heather M. Anderson-Keightly; Sarah Abou Alaiwi; Talia D. Rosenbloom; Penina S. Stewart; Matthew D. Galsky; Toni K. Choueiri; Deborah B. Doroshow

doi:10.1016/j.ccell.2020.10.023

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

Andrew L. Schmidt, Ziad Bakouny, Sheena Bhalla, John A. Steinharter, Douglas A. Tremblay, Mark M. Awad, Alaina J. Kessler, Robert I. Haddad, Michelle Evans, Fiona Busser, Michael Wotman, Catherine R. Curran, Brittney S. Zimmerman, Gabrielle Bouchard, Tomi Jun, Pier V. Nuzzo, Qian Qin, Laure Hirsch, Jonathan Feld, Kaitlin M. KelleherDanielle Seidman, Hsin Hui Huang, Heather M. Anderson-Keightly, Sarah Abou Alaiwi, Talia D. Rosenbloom, Penina S. Stewart, Matthew D. Galsky, Toni K. Choueiri, Deborah B. Doroshow

Research output: Contribution to journal › Letter › peer-review

54 Scopus citations

Original language	English
Pages (from-to)	769-770
Number of pages	2
Journal	Cancer Cell
Volume	38
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2020.10.023
State	Published - 14 Dec 2020

Access to Document

10.1016/j.ccell.2020.10.023

Cite this

Schmidt, A. L., Bakouny, Z., Bhalla, S., Steinharter, J. A., Tremblay, D. A., Awad, M. M., Kessler, A. J., Haddad, R. I., Evans, M., Busser, F., Wotman, M., Curran, C. R., Zimmerman, B. S., Bouchard, G., Jun, T., Nuzzo, P. V., Qin, Q., Hirsch, L., Feld, J., ... Doroshow, D. B. (2020). Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell, 38(6), 769-770. https://doi.org/10.1016/j.ccell.2020.10.023

@article{b1ba4b020f4649d283e2600963f5c2e2,

title = "Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study",

author = "Schmidt, {Andrew L.} and Ziad Bakouny and Sheena Bhalla and Steinharter, {John A.} and Tremblay, {Douglas A.} and Awad, {Mark M.} and Kessler, {Alaina J.} and Haddad, {Robert I.} and Michelle Evans and Fiona Busser and Michael Wotman and Curran, {Catherine R.} and Zimmerman, {Brittney S.} and Gabrielle Bouchard and Tomi Jun and Nuzzo, {Pier V.} and Qian Qin and Laure Hirsch and Jonathan Feld and Kelleher, {Kaitlin M.} and Danielle Seidman and Huang, {Hsin Hui} and Anderson-Keightly, {Heather M.} and {Abou Alaiwi}, Sarah and Rosenbloom, {Talia D.} and Stewart, {Penina S.} and Galsky, {Matthew D.} and Choueiri, {Toni K.} and Doroshow, {Deborah B.}",

note = "Funding Information: The authors report the following conflicts of interest: A.L.S., educational travel support from Pfizer and Astellas; Z.B., non-financial support from Bristol Myers Squibb and research support from Genentech/ImCore; M.M.A., research support from Bristol-Myers Squibb Lilly, AstraZeneca, and Genentech and a consulting/advisory role with Bristol-Myers Squibb, Lilly, AstraZeneca, Genentech, Merck, Achilles, and Abbvie; R.I.H., consulting/advisory role with BMS, Merck, Pfizer, Genetech, Astra Zeneca, and GSK and research grant/funding from Merck, BMS, Pfizer, Genentech, GSK, and Astra Zeneca. M.D.G. reports stock from Rappta Therapeutics; a consulting/advisory role for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Alleron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, and Dragonfly Therapeutics; and institutional research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche. T.K.C. reports research support from AstraZeneca, Alexion, Bayer, Bristol MyersSquibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, 16 Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; honoraria, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly Oncology; a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Pionyr, Tempest, Lilly Ventures; owns stocks of Pionyr and Tempest; leadership roles as Director of Genitourinary Oncology Division at Dana-Farber and past President of Medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, KidneyCan Advisory board, Kidney cancer Research Summit co-chair (2019–present); patents, royalties, or other intellectual properties including International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application 17 No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017; and travel, accommodations, and expenses, in relation to consulting, advisory roles, or honoraria; medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, and others). T.K.C.{\textquoteright}s institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T.K.C. has mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components. D.B.D. reports consulting/advisory roles with Ipsen, Boeringer Ingelheim, Atheneum Partners, Boston Healthcare Associates, Dedham Group, and Guidepoint Global Advisors and travel expenses from Ipsen. Funding Information: The authors report the following conflicts of interest: A.L.S. educational travel support from Pfizer and Astellas; Z.B. non-financial support from Bristol Myers Squibb and research support from Genentech/ImCore; M.M.A. research support from Bristol-Myers Squibb Lilly, AstraZeneca, and Genentech and a consulting/advisory role with Bristol-Myers Squibb, Lilly, AstraZeneca, Genentech, Merck, Achilles, and Abbvie; R.I.H. consulting/advisory role with BMS, Merck, Pfizer, Genetech, Astra Zeneca, and GSK and research grant/funding from Merck, BMS, Pfizer, Genentech, GSK, and Astra Zeneca. M.D.G. reports stock from Rappta Therapeutics; a consulting/advisory role for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Alleron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, and Dragonfly Therapeutics; and institutional research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche. T.K.C. reports research support from AstraZeneca, Alexion, Bayer, Bristol MyersSquibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Ipsen, 16 Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; honoraria, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly Oncology; a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Pionyr, Tempest, Lilly Ventures; owns stocks of Pionyr and Tempest; leadership roles as Director of Genitourinary Oncology Division at Dana-Farber and past President of Medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, KidneyCan Advisory board, Kidney cancer Research Summit co-chair (2019–present); patents, royalties, or other intellectual properties including International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application 17 No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017; and travel, accommodations, and expenses, in relation to consulting, advisory roles, or honoraria; medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, and others). T.K.C.{\textquoteright}s institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T.K.C. has mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components. D.B.D. reports consulting/advisory roles with Ipsen, Boeringer Ingelheim, Atheneum Partners, Boston Healthcare Associates, Dedham Group, and Guidepoint Global Advisors and travel expenses from Ipsen.",

year = "2020",

month = dec,

day = "14",

doi = "10.1016/j.ccell.2020.10.023",

language = "English",

volume = "38",

pages = "769--770",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

Schmidt, AL, Bakouny, Z, Bhalla, S, Steinharter, JA, Tremblay, DA, Awad, MM, Kessler, AJ, Haddad, RI, Evans, M, Busser, F, Wotman, M, Curran, CR, Zimmerman, BS, Bouchard, G, Jun, T, Nuzzo, PV, Qin, Q, Hirsch, L, Feld, J, Kelleher, KM, Seidman, D, Huang, HH, Anderson-Keightly, HM, Abou Alaiwi, S, Rosenbloom, TD, Stewart, PS, Galsky, MD, Choueiri, TK & Doroshow, DB 2020, 'Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study', Cancer Cell, vol. 38, no. 6, pp. 769-770. https://doi.org/10.1016/j.ccell.2020.10.023

TY - JOUR

T1 - Cancer Care Disparities during the COVID-19 Pandemic

T2 - COVID-19 and Cancer Outcomes Study

AU - Schmidt, Andrew L.

AU - Bakouny, Ziad

AU - Bhalla, Sheena

AU - Steinharter, John A.

AU - Tremblay, Douglas A.

AU - Awad, Mark M.

AU - Kessler, Alaina J.

AU - Haddad, Robert I.

AU - Evans, Michelle

AU - Busser, Fiona

AU - Wotman, Michael

AU - Curran, Catherine R.

AU - Zimmerman, Brittney S.

AU - Bouchard, Gabrielle

AU - Jun, Tomi

AU - Nuzzo, Pier V.

AU - Qin, Qian

AU - Hirsch, Laure

AU - Feld, Jonathan

AU - Kelleher, Kaitlin M.

AU - Seidman, Danielle

AU - Huang, Hsin Hui

AU - Anderson-Keightly, Heather M.

AU - Abou Alaiwi, Sarah

AU - Rosenbloom, Talia D.

AU - Stewart, Penina S.

AU - Galsky, Matthew D.

AU - Choueiri, Toni K.

AU - Doroshow, Deborah B.

N1 - Funding Information: The authors report the following conflicts of interest: A.L.S., educational travel support from Pfizer and Astellas; Z.B., non-financial support from Bristol Myers Squibb and research support from Genentech/ImCore; M.M.A., research support from Bristol-Myers Squibb Lilly, AstraZeneca, and Genentech and a consulting/advisory role with Bristol-Myers Squibb, Lilly, AstraZeneca, Genentech, Merck, Achilles, and Abbvie; R.I.H., consulting/advisory role with BMS, Merck, Pfizer, Genetech, Astra Zeneca, and GSK and research grant/funding from Merck, BMS, Pfizer, Genentech, GSK, and Astra Zeneca. M.D.G. reports stock from Rappta Therapeutics; a consulting/advisory role for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Alleron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, and Dragonfly Therapeutics; and institutional research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche. T.K.C. reports research support from AstraZeneca, Alexion, Bayer, Bristol MyersSquibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, 16 Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; honoraria, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly Oncology; a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Pionyr, Tempest, Lilly Ventures; owns stocks of Pionyr and Tempest; leadership roles as Director of Genitourinary Oncology Division at Dana-Farber and past President of Medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, KidneyCan Advisory board, Kidney cancer Research Summit co-chair (2019–present); patents, royalties, or other intellectual properties including International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application 17 No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017; and travel, accommodations, and expenses, in relation to consulting, advisory roles, or honoraria; medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, and others). T.K.C.’s institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T.K.C. has mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components. D.B.D. reports consulting/advisory roles with Ipsen, Boeringer Ingelheim, Atheneum Partners, Boston Healthcare Associates, Dedham Group, and Guidepoint Global Advisors and travel expenses from Ipsen. Funding Information: The authors report the following conflicts of interest: A.L.S. educational travel support from Pfizer and Astellas; Z.B. non-financial support from Bristol Myers Squibb and research support from Genentech/ImCore; M.M.A. research support from Bristol-Myers Squibb Lilly, AstraZeneca, and Genentech and a consulting/advisory role with Bristol-Myers Squibb, Lilly, AstraZeneca, Genentech, Merck, Achilles, and Abbvie; R.I.H. consulting/advisory role with BMS, Merck, Pfizer, Genetech, Astra Zeneca, and GSK and research grant/funding from Merck, BMS, Pfizer, Genentech, GSK, and Astra Zeneca. M.D.G. reports stock from Rappta Therapeutics; a consulting/advisory role for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Alleron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, and Dragonfly Therapeutics; and institutional research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche. T.K.C. reports research support from AstraZeneca, Alexion, Bayer, Bristol MyersSquibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Ipsen, 16 Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; honoraria, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly Oncology; a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc. Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Pionyr, Tempest, Lilly Ventures; owns stocks of Pionyr and Tempest; leadership roles as Director of Genitourinary Oncology Division at Dana-Farber and past President of Medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, KidneyCan Advisory board, Kidney cancer Research Summit co-chair (2019–present); patents, royalties, or other intellectual properties including International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application 17 No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017; and travel, accommodations, and expenses, in relation to consulting, advisory roles, or honoraria; medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, and others). T.K.C.’s institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T.K.C. has mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components. D.B.D. reports consulting/advisory roles with Ipsen, Boeringer Ingelheim, Atheneum Partners, Boston Healthcare Associates, Dedham Group, and Guidepoint Global Advisors and travel expenses from Ipsen.

PY - 2020/12/14

Y1 - 2020/12/14

UR - http://www.scopus.com/inward/record.url?scp=85096614826&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.10.023

DO - 10.1016/j.ccell.2020.10.023

M3 - Letter

C2 - 33176161

AN - SCOPUS:85096614826

SN - 1535-6108

VL - 38

SP - 769

EP - 770

JO - Cancer Cell

JF - Cancer Cell

IS - 6

ER -